Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
Abdurrahman Tufan, Clinical Consultant and Instructor at Gazi University, shared a post on LinkedIn:
“I’m very pleased to share our new publication in Seminars in Arthritis and Rheumatism:
‘Biologic biologic and biologic JAK inhibitor combination therapy in refractory systemic autoinflammatory diseases.’
Our findings demonstrate the potential of combination targeted therapy to achieve sustained disease control in selected patients with severe and refractory systemic autoinflammatory diseases (SAIDs), including those with persistent inflammation and limited therapeutic options.
In this retrospective longitudinal cohort from the NIH Inflammatory Disease Section, we evaluated advanced combination therapy (ACT) using biologics and or JAK inhibitors in patients with difficult to treat SAIDs.
Among 38 patients, 65 ACT regimens were administered. Following multiple treatment trials:
- 55.3 percent achieved a complete response
- 31.6 percent achieved a partial response
- 68 percent of patients remained on combination therapy at final follow up
- Median duration of ACT was 5 years (range 11 to 186 months)
I am very grateful to all of my co authors and colleagues who contributed to this study, and especially to Daniel L. Kastner, whose mentorship and vision have profoundly influenced our work in autoinflammatory diseases.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 01:44Patrick James Lynch: Mother of a Thousand Sons Premieres at BDC 2026
-
Sep 19, 2026, 01:41Genetic Fate Mapping Reveals Endothelial Cells During Venous Thrombus Resolution – RPTH Journal
-
Sep 19, 2026, 01:39Mostafa Hammam: Three Different Platelet Defects – One Common Symptom
-
Sep 19, 2026, 01:38Jeff Sternlicht: A Heart Attack Should Not Be the Starting Line
-
Sep 19, 2026, 01:28Luis Oliverio Ambriz Garcia: Key Points From the ASH 2026 Guidelines on Iron Deficiency
-
Sep 19, 2026, 01:27Farjah Algahtani: A New Era in the Treatment of Transfusion-Dependent Thalassaemia
-
Sep 19, 2026, 01:24Aravind Palraj: 2025 EULAR Behçet’s Syndrome Update – 5 Practical Take-Home Points
-
Sep 19, 2026, 01:23Chokri Ben Lamine: Cemdisiran in PNH – Why Combine Complement Therapies?
-
Sep 19, 2026, 01:19Stefano Garzon: Comparing DOACs SAPT and DAPT After LAAO